Knee osteoarthritis continues to be a significant clinical challenge given its high prevalence and impact on patients' quality of life. Although autologous Platelet-Rich Plasma (PRP) has gained ground as a therapeutic option for modulating inflammation and promoting tissue regeneration, not everyone responds favorably to this approach.

Recently, a pioneering study^[1] was conducted by the team of orthopedic surgeons and researchers from the Arthroscopic Surgery Unit and the Advanced Biological Therapy Unit at MiKS Hospital. Together, they evaluated the feasibility, safety, and efficacy of allogeneic PRP in patients with knee osteoarthritis who did not respond to autologous treatment.

Published in Cartilage, this prospective clinical study demonstrates that allogeneic PRP—derived from responder donors—may be a safe and effective alternative for pain relief and functional improvement in this population.

The administration protocol consisted of three intra-articular injections of allogeneic PRP, performed in an outpatient setting. The results showed a significant reduction in pain scores and improvement in joint function, with no serious adverse effects related to the treatment reported.

These findings open the door to a promising therapeutic option for patients with limitations in obtaining quality autologous PRP, expanding the therapeutic arsenal available for the personalized management of osteoarthritis. In this study, the therapy showed sustained efficacy after one year of follow-up, supporting its potential as a complementary option in this patient profile. Future additional clinical trials that analyze donor and recipient biological factors in depth will allow for a better understanding and improvement of this type of treatment.

^[1] Sánchez M, Guadilla J, Jorquera C, et al. Intra-articular Injections of Allogeneic Platelet-Rich Plasma from Responder Patients for the Treatment of Knee Osteoarthritis: A Pilot and Feasibility Clinical Trial. CARTILAGE. 2025;0(0). doi:10.1177/19476035251355522